In last trading session, Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL) saw 1.19 million shares changing hands with its beta currently measuring 1.58. Company’s recent per share price level of $17.09 trading at $0.52 or 3.14% at ring of the bell on the day assigns it a market valuation of $1.54B. That closing price of AVDL’s stock is at a discount of -0.88% from its 52-week high price of $17.24 and is indicating a premium of 53.19% from its 52-week low price of $8.00. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.87 million shares which gives us an average trading volume of 1.30 million if we extend that period to 3-months.
Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL) trade information
Upright in the green during last session for gaining 3.14%, in the last five days AVDL remained trading in the green while hitting it’s week-highest on Thursday, 03/21/24 when the stock touched $17.09 price level, adding 0.06% to its value on the day. Avadel Pharmaceuticals plc ADR’s shares saw a change of 21.03% in year-to-date performance and have moved 6.15% in past 5-day. Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL) showed a performance of 34.78% in past 30-days. Number of shares sold short was 10.74 million shares which calculate 9.72 days to cover the short interests.
Avadel Pharmaceuticals plc ADR (AVDL) estimates and forecasts
Statistics highlight that Avadel Pharmaceuticals plc ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company added 52.05% of value to its shares in past 6 months, showing an annual growth rate of 77.00% while that of industry is 11.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 56.30% in the current quarter and calculating 85.50% increase in the next quarter. This year revenue growth is estimated to rise 480.00% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $26.67 million for the same. And 9 analysts are in estimates of company making revenue of $36.6 million in the next quarter that will end on Jun 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.78% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 78.11% while estimates for its earnings growth in next 5 years are of 15.00%.
AVDL Dividends
Avadel Pharmaceuticals plc ADR is more likely to be releasing its next quarterly report on March 04 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL)’s Major holders
Insiders are in possession of 4.90% of company’s total shares while institution are holding 63.72 percent of that, with stock having share float percentage of 67.00%. Investors also watch the number of corporate investors in a company very closely, which is 63.72% institutions for Avadel Pharmaceuticals plc ADR that are currently holding shares of the company. Janus Henderson Group PLC is the top institutional holder at AVDL for having 11.13 million shares of worth $190.13 million. And as of Dec 30, 2023, it was holding 12.28% of the company’s outstanding shares.
The second largest institutional holder is RTW Investments LP, which was holding about 6.95 million shares on Dec 30, 2023. The number of shares represents firm’s hold over 7.67% of outstanding shares, having a total worth of $118.74 million.
On the other hand, Janus Henderson Global Life Sciences Fund and Janus Henderson Venture Fund are the top two Mutual Funds which own company’s shares. As of Dec 30, 2023, the former fund manager was holding 2.9 million shares of worth $49.6 million or 3.20% of the total outstanding shares. The later fund manager was in possession of 1.18 million shares on Dec 30, 2023, making its stake of worth around $20.19 million in the company or a holder of 1.30% of company’s stock.
